These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16251338)

  • 1. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis.
    Solomon AW; Mohammed Z; Massae PA; Shao JF; Foster A; Mabey DC; Peeling RW
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4804-6. PubMed ID: 16251338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
    J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
    Ramadhani AM; Derrick T; Macleod D; Massae P; Malisa A; Mbuya K; Mtuy T; Makupa W; Roberts CH; Bailey RL; Mabey DCW; Holland MJ; Burton MJ
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007559. PubMed ID: 31306419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass treatment with single-dose azithromycin for trachoma.
    Solomon AW; Holland MJ; Alexander ND; Massae PA; Aguirre A; Natividad-Sancho A; Molina S; Safari S; Shao JF; Courtright P; Peeling RW; West SK; Bailey RL; Foster A; Mabey DC
    N Engl J Med; 2004 Nov; 351(19):1962-71. PubMed ID: 15525721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
    Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
    Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands.
    Marks M; Bottomley C; Tome H; Pitakaka R; Butcher R; Sokana O; Kako H; Solomon AW; Mabey DC
    Sex Transm Infect; 2016 Jun; 92(4):261-5. PubMed ID: 26888658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
    Pickering H; Ramadhani AM; Massae P; Mafuru E; Malisa A; Mbuya K; Makupa W; Mtuy T; Derrick T; Houghton J; Bailey RL; Mabey DCW; Burton MJ; Holland MJ
    Front Public Health; 2022; 10():1015714. PubMed ID: 36324475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azithromycin for the treatment and control of trachoma.
    Burton MJ; Frick KD; Bailey RL; Bowman RJ
    Expert Opin Pharmacother; 2002 Feb; 3(2):113-20. PubMed ID: 11829725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping azithromycin mass drug administration for trachoma: A systematic review.
    Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
    Morberg DP; Alemayehu W; Melese M; Lakew T; Sisay A; Zhou Z; Cevallos V; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
    Ophthalmic Epidemiol; 2019 Feb; 26(1):19-26. PubMed ID: 30153085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas?
    Bird M; Dawson CR; Schachter JS; Miao Y; Shama A; Osman A; Bassem A; Lietman TM
    J Infect Dis; 2003 May; 187(10):1669-73. PubMed ID: 12721948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversity of Chlamydia trachomatis in Trachoma-Hyperendemic Communities Treated With Azithromycin.
    Chin SA; Morberg DP; Alemayehu W; Melese M; Lakew T; Chen MC; Zhou Z; Doan T; Cevallos V; Lietman TM; Keenan JD
    Am J Epidemiol; 2018 Sep; 187(9):1840-1845. PubMed ID: 29617922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Foster A; Bailey RL; Mabey DC
    Lancet; 2005 Oct; 366(9493):1296-300. PubMed ID: 16214600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.
    West SK; Munoz BE; Mkocha H; Gaydos C; Quinn T
    Ophthalmic Epidemiol; 2015; 22(3):170-5. PubMed ID: 26158574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial.
    Oldenburg CE; Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Gaynor BD; Keenan JD; Lietman TM
    Am J Trop Med Hyg; 2018 Feb; 98(2):389-395. PubMed ID: 29260659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma.
    Hong KC; Schachter J; Moncada J; Zhou Z; House J; Lietman TM
    Emerg Infect Dis; 2009 Jul; 15(7):1088-90. PubMed ID: 19624926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular Chlamydia trachomatis infection: elimination with mass drug administration.
    Wolle MA; West SK
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):189-200. PubMed ID: 30698042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal.
    Fry AM; Jha HC; Lietman TM; Chaudhary JS; Bhatta RC; Elliott J; Hyde T; Schuchat A; Gaynor B; Dowell SF
    Clin Infect Dis; 2002 Aug; 35(4):395-402. PubMed ID: 12145722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment.
    Gower EW; Solomon AW; Burton MJ; Aguirre A; Muñoz B; Bailey R; Holland M; Makalo P; Massae P; Mkocha H; Mabey DC; West SK
    Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):4767-71. PubMed ID: 17065486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.